Commentary: Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

Jeremy W Jacobs; Garrett S Booth; Elizabeth S Allen; Brian D Adkins

doi:10.3389/fimmu.2023.1133382

Commentary: Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

Front Immunol. 2023 Jan 27:14:1133382. doi: 10.3389/fimmu.2023.1133382. eCollection 2023.

Authors

Jeremy W Jacobs¹, Garrett S Booth², Elizabeth S Allen³, Brian D Adkins⁴

Affiliations

¹ Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, United States.
² Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.
³ Department of Pathology, University of California San Diego, La Jolla, CA, United States.
⁴ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.

No abstract available

Keywords: alloantibody; alloimmunization; daratumumab; immunohematology; pre-transfusion testing; red blood cell antibodies; sickle cell disease; transfusion medicine.

Publication types

Comment

MeSH terms

Anemia, Sickle Cell* / immunology
Antibodies, Monoclonal / adverse effects
Erythrocytes* / immunology
Humans

Substances

daratumumab
Antibodies, Monoclonal